Skip to main content
NCBI home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1996 May;5(5):874–882. doi: 10.1002/pro.5560050509

Interaction of subtilisins with serpins.

T Komiyama 1, H Grøn 1, P A Pemberton 1, G S Salvesen 1
PMCID: PMC2143405  PMID: 8732759

Abstract

Serpins are well-characterized inhibitors of the chymotrypsin family serine proteinases. We have investigated the interaction of two serpins with members of the subtilisin family, proteinases that possess a similar catalytic mechanism to the chymotrypsins, but a totally different scaffold. We demonstrate that alpha 1 proteinase inhibitor inhibits subtilisin Carlsberg and proteinase K, and alpha 1 antichymotrypsin inhibits proteinase K, but not subtilisin Carlsberg. When inhibition occurs, the rate of formation and stability of the complexes are similar to those formed between serpins and chymotrypsin family members. However, inhibition of subtilisins is characterized by large partition ratios where more than four molecules of each serpin are required to inhibit one subtilisin molecule. The partition ratio is caused by the serpins acting as substrates or inhibitors. The ratio decreases as temperature is elevated in the range 0-45 degrees C, indicating that the serpins are more efficient inhibitors at high temperature. These aspects of the subtilisin interaction are all observed during inhibition of chymotrypsin family members by serpins, indicating that serpins accomplish inhibition of these two distinct proteinase families by the same mechanism.

Full Text

The Full Text of this article is available as a PDF (3.2 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe O., Kuromizu K. Stoichiometry of the interaction of human plasma alpha 1-proteinase inhibitor with subtilisin BPN'. J Biochem. 1989 Jan;105(1):66–71. doi: 10.1093/oxfordjournals.jbchem.a122621. [DOI] [PubMed] [Google Scholar]
  2. Anderson E. D., Thomas L., Hayflick J. S., Thomas G. Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant. J Biol Chem. 1993 Nov 25;268(33):24887–24891. [PubMed] [Google Scholar]
  3. Barr P. J. Mammalian subtilisins: the long-sought dibasic processing endoproteases. Cell. 1991 Jul 12;66(1):1–3. doi: 10.1016/0092-8674(91)90129-m. [DOI] [PubMed] [Google Scholar]
  4. Baugh R. J., Travis J. Human leukocyte granule elastase: rapid isolation and characterization. Biochemistry. 1976 Feb 24;15(4):836–841. doi: 10.1021/bi00649a017. [DOI] [PubMed] [Google Scholar]
  5. Beatty K., Bieth J., Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem. 1980 May 10;255(9):3931–3934. [PubMed] [Google Scholar]
  6. Bigler T. L., Lu W., Park S. J., Tashiro M., Wieczorek M., Wynn R., Laskowski M., Jr Binding of amino acid side chains to preformed cavities: interaction of serine proteinases with turkey ovomucoid third domains with coded and noncoded P1 residues. Protein Sci. 1993 May;2(5):786–799. doi: 10.1002/pro.5560020509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bode W., Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem. 1992 Mar 1;204(2):433–451. doi: 10.1111/j.1432-1033.1992.tb16654.x. [DOI] [PubMed] [Google Scholar]
  8. Brennan S. O., Nakayama K. Furin has the proalbumin substrate specificity and serpin inhibitory properties of an in situ hepatic convertase. FEBS Lett. 1994 Jan 31;338(2):147–151. doi: 10.1016/0014-5793(94)80353-6. [DOI] [PubMed] [Google Scholar]
  9. Carrell R. W., Stein P. E., Fermi G., Wardell M. R. Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994 Apr 15;2(4):257–270. doi: 10.1016/s0969-2126(00)00028-9. [DOI] [PubMed] [Google Scholar]
  10. Cooperman B. S., Stavridi E., Nickbarg E., Rescorla E., Schechter N. M., Rubin H. Antichymotrypsin interaction with chymotrypsin. Partitioning of the complex. J Biol Chem. 1993 Nov 5;268(31):23616–23625. [PubMed] [Google Scholar]
  11. Gettins P., Patston P. A., Schapira M. Structure and mechanism of action of serpins. Hematol Oncol Clin North Am. 1992 Dec;6(6):1393–1408. [PubMed] [Google Scholar]
  12. Greagg M. A., Brauer A. B., Leatherbarrow R. J. Expression and kinetic characterization of barley chymotrypsin inhibitors 1a and 1b. Biochim Biophys Acta. 1994 Jun 30;1222(2):179–186. doi: 10.1016/0167-4889(94)90167-8. [DOI] [PubMed] [Google Scholar]
  13. Grøn H., Breddam K. Interdependency of the binding subsites in subtilisin. Biochemistry. 1992 Sep 22;31(37):8967–8971. doi: 10.1021/bi00152a037. [DOI] [PubMed] [Google Scholar]
  14. Grøn H., Meldal M., Breddam K. Extensive comparison of the substrate preferences of two subtilisins as determined with peptide substrates which are based on the principle of intramolecular quenching. Biochemistry. 1992 Jul 7;31(26):6011–6018. doi: 10.1021/bi00141a008. [DOI] [PubMed] [Google Scholar]
  15. Hood D. B., Huntington J. A., Gettins P. G. Alpha 1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry. 1994 Jul 19;33(28):8538–8547. doi: 10.1021/bi00194a020. [DOI] [PubMed] [Google Scholar]
  16. Laskowski M., Jr, Kato I., Ardelt W., Cook J., Denton A., Empie M. W., Kohr W. J., Park S. J., Parks K., Schatzley B. L. Ovomucoid third domains from 100 avian species: isolation, sequences, and hypervariability of enzyme-inhibitor contact residues. Biochemistry. 1987 Jan 13;26(1):202–221. doi: 10.1021/bi00375a028. [DOI] [PubMed] [Google Scholar]
  17. Lawrence D. A., Ginsburg D., Day D. E., Berkenpas M. B., Verhamme I. M., Kvassman J. O., Shore J. D. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem. 1995 Oct 27;270(43):25309–25312. doi: 10.1074/jbc.270.43.25309. [DOI] [PubMed] [Google Scholar]
  18. Loebermann H., Tokuoka R., Deisenhofer J., Huber R. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol. 1984 Aug 15;177(3):531–557. [PubMed] [Google Scholar]
  19. Longstaff C., Gaffney P. J. Serpin-serine protease binding kinetics: alpha 2-antiplasmin as a model inhibitor. Biochemistry. 1991 Jan 29;30(4):979–986. doi: 10.1021/bi00218a014. [DOI] [PubMed] [Google Scholar]
  20. Mast A. E., Enghild J. J., Salvesen G. Conformation of the reactive site loop of alpha 1-proteinase inhibitor probed by limited proteolysis. Biochemistry. 1992 Mar 17;31(10):2720–2728. doi: 10.1021/bi00125a012. [DOI] [PubMed] [Google Scholar]
  21. Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem. 1987 Jul 25;262(21):10035–10038. [PubMed] [Google Scholar]
  22. Morihara K., Oka T., Tsuzuki H. Subtilisin BPN': kinetic study with oligopeptides. Arch Biochem Biophys. 1970 Jun;138(2):515–525. doi: 10.1016/0003-9861(70)90376-0. [DOI] [PubMed] [Google Scholar]
  23. Morii M., Travis J. Amino acid sequence at the reactive site of human alpha 1-antichymotrypsin. J Biol Chem. 1983 Nov 10;258(21):12749–12752. [PubMed] [Google Scholar]
  24. Patston P. A., Gettins P., Beechem J., Schapira M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry. 1991 Sep 10;30(36):8876–8882. doi: 10.1021/bi00100a022. [DOI] [PubMed] [Google Scholar]
  25. Patston P. A. Studies on inhibition of neutrophil cathepsin G by alpha 1-antichymotrypsin. Inflammation. 1995 Feb;19(1):75–81. doi: 10.1007/BF01534382. [DOI] [PubMed] [Google Scholar]
  26. Perona J. J., Craik C. S. Structural basis of substrate specificity in the serine proteases. Protein Sci. 1995 Mar;4(3):337–360. doi: 10.1002/pro.5560040301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rawlings N. D., Barrett A. J. Families of serine peptidases. Methods Enzymol. 1994;244:19–61. doi: 10.1016/0076-6879(94)44004-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Robertus J. D., Alden R. A., Birktoft J. J., Kraut J., Powers J. C., Wilcox P. E. An x-ray crystallographic study of the binding of peptide chloromethyl ketone inhibitors to subtilisin BPN'. Biochemistry. 1972 Jun 20;11(13):2439–2449. doi: 10.1021/bi00763a009. [DOI] [PubMed] [Google Scholar]
  29. Rubin H., Wang Z. M., Nickbarg E. B., McLarney S., Naidoo N., Schoenberger O. L., Johnson J. L., Cooperman B. S. Cloning, expression, purification, and biological activity of recombinant native and variant human alpha 1-antichymotrypsins. J Biol Chem. 1990 Jan 15;265(2):1199–1207. [PubMed] [Google Scholar]
  30. Schechter N. M., Jordan L. M., James A. M., Cooperman B. S., Wang Z. M., Rubin H. Reaction of human chymase with reactive site variants of alpha 1-antichymotrypsin. Modulation of inhibitor versus substrate properties. J Biol Chem. 1993 Nov 5;268(31):23626–23633. [PubMed] [Google Scholar]
  31. Schechter N. M., Sprows J. L., Schoenberger O. L., Lazarus G. S., Cooperman B. S., Rubin H. Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J Biol Chem. 1989 Dec 15;264(35):21308–21315. [PubMed] [Google Scholar]
  32. Schreuder H. A., de Boer B., Dijkema R., Mulders J., Theunissen H. J., Grootenhuis P. D., Hol W. G. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol. 1994 Jan;1(1):48–54. doi: 10.1038/nsb0194-48. [DOI] [PubMed] [Google Scholar]
  33. Siezen R. J., de Vos W. M., Leunissen J. A., Dijkstra B. W. Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases. Protein Eng. 1991 Oct;4(7):719–737. doi: 10.1093/protein/4.7.719. [DOI] [PubMed] [Google Scholar]
  34. Stein P. E., Carrell R. W. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol. 1995 Feb;2(2):96–113. doi: 10.1038/nsb0295-96. [DOI] [PubMed] [Google Scholar]
  35. Takeuchi Y., Noguchi S., Satow Y., Kojima S., Kumagai I., Miura K., Nakamura K. T., Mitsui Y. Molecular recognition at the active site of subtilisin BPN': crystallographic studies using genetically engineered proteinaceous inhibitor SSI (Streptomyces subtilisin inhibitor). Protein Eng. 1991 Jun;4(5):501–508. doi: 10.1093/protein/4.5.501. [DOI] [PubMed] [Google Scholar]
  36. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  37. Watanabe M., Hirano A., Stenglein S., Nelson J., Thomas G., Wong T. C. Engineered serine protease inhibitor prevents furin-catalyzed activation of the fusion glycoprotein and production of infectious measles virus. J Virol. 1995 May;69(5):3206–3210. doi: 10.1128/jvi.69.5.3206-3210.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES